Search
Recombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigational[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of
Pixantrone
go.drugbank.com/drugs/DB06193ApprovedWithdrawnIt is similar in structure to anthracyclines such as mitoxantrone, but exerts fewer toxic effects on cardiac tissue. [2] The lower cardio-toxic effects of pixantrone may be explained, in part, by its redox … Pixantrone dimaleate, administered intravenously, was designed by Cell Therapeutics Incorporated as an alternative second line therapy in refractory or relapsed NHL.
Semaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigationalThe use of salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, has not been proven to be safe or effective. … [A186053] In June 2021, semaglutide was approved by the FDA for chronic weight management in adults with general obesity or overweight who have at least one weight-related condition, marking semaglutide
Ocrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigational[A31741] In September 2024, a formulation of ocrelizumab containing [hyaluronidase (human recombinant)] was approved by the US FDA. … It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada.
Recombinant stabilized RSV B prefusion F antigen
go.drugbank.com/drugs/DB18714ApprovedInvestigational[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of
Etuvetidigene Autotemcel
go.drugbank.com/drugs/DB17593ApprovedInvestigational[L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system. … [L54698] First approved by the FDA on December 9, 2025, etuvetidigene autotemcel is used to treat Wiskott–Aldrich syndrome (WAS) in selected pediatric and adult patients.
Pegfilgrastim
go.drugbank.com/drugs/DB00019ApprovedInvestigational[A187607] First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection. … [A187601] The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer
Daridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigational[A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. … Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning.
Topotecan
go.drugbank.com/drugs/DB01030ApprovedInvestigationalIt works by inhibiting DNA topoisomerases, type I.
Ibrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalApril 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. … [L45894] Ibrutinib was approved by the EMA in October 2014 [L45884] and by Health Canada in November 2014.